Workgroup Member Affiliations and Disclosures

Maria C. Carrillo is a full-time employee of the Alzheimer's Association and has a daughter in the neuroscience program at USC. She has no financial conflicts to disclose.

Jeffrey L. Cummings, consultation to Acadia, Actinogen, Acumen, AlphaCognition, Aprinoia, AriBio, Artery, Biogen, BioVie, Cassava, Cerecin, Diadem, EIP Pharma, Eisai, GemVax, Genentech, GAP Innovations, Janssen, Jocasta, Karuna, Lilly, Lundbeck, LSP, Merck, NervGen, Novo Nordisk, Oligomerix, Optoceutics, Ono, Otsuka, PRODEO, Prothena, ReMYND, Roche, Sage Therapeutics, Signant Health, Simcere, Suven, SynapseBio, TrueBinding, Vaxxinity, and Wren pharmaceutical, assessment, and investment companies. He is supported by NIGMS grant P20GM109025; NINDS grant U01NS093334; NIA grant R01AG053798; NIA grant P20AG068053; NIA grant P30AG072959; NIA grant R35AG71476; Alzheimer's Disease Drug Discovery Foundation (ADDF); Ted and Maria Quirk Endowment; and the Joy Chambers-Grundy Endowment.

Douglas Galasko consultant for Eisai, GE Healthcare, Eli Lilly, DSMB for Artery Therapeutics.

Milos D. Ikonomovic has no disclosures.

Renaud La Joie has no disclosures.

Susan M. Landau, DSMB for KeifeRX and NIH IPAT study, speaking fees from Eisai.

Jorge Llibre-Guerra has nothing to disclose.

Catherine Mummery, advisory board/consultancy Biogen, Roche, WAVE, IONIS, Prevail, Lilly; received grant from Biogen; speaker for sponsored events for Biogen, Roche, EISAI, IONIS, Lilly.

Rik Ossenkoppele, research support from Avid Radiopharmaceuticals, Janssen Research & Development, Roche, Quanterix and Optina Diagnostics. He has given lectures in symposia sponsored by GE Healthcare, and is a consultant for Asceneuron.

Julie Price, supported by NAI R01AG062559; P01AG036694;T32AG066592; R01AG076153; U19AG068054; R01AG079142.

Shannon Risacher has nothing to disclose.

Claire Sexton is a full time employee of the Alzheimer's Association.

Last updated: October 2023

Ruben Smith has given a lecture in a symposium sponsored by Roche.

Christopher H. van Dyck has provided consultation to Eisai, Roche, Ono, and Cerevel and receives grant support for clinical trials from Lilly, Biogen, Eisai, Roche, Genentech, UCB, and Cerevel.

Last updated: October 2023